A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs). SUBTITLE: Amendment to Include Switches From Additional Antiretroviral Regimens
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Abacavir; Atazanavir; Cobicistat; Darunavir; Efavirenz; Elvitegravir; Lopinavir; Nevirapine; Rilpivirine; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms DRIVE-SHIFT
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 18 Sep 2024 This trial has been completed in Spain (End date: 2023-09-05) according to European Clinical Trials Database record.
- 13 Sep 2023 Status changed from active, no longer recruiting to completed.
- 26 Oct 2022 Results (of three phase 3 studies DRIVE-FORWARD, DRIVE- AHEAD and DRIVE-SHIFT) assessing Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen presented at the 16th International Congress on Drug Therapy and HIV Infection